Company: IMNN
Filing Date: 2025-05-13
Form Type: S-1/A
Source: 0001641172-25-009814
Chunk: 2

Company: Imunon, Inc.
Filing Date: 2025-05-13
Form: S-1/A
Chunk 2
---
 COMMON WARRANTS TO PURCHASE 45,000,000 SHARES OF COMMON STOCK*

UP TO 15,000,000 PRE-FUNDED WARRANTS TO PURCHASE 15,000,000 SHARES OF COMMON STOCK

UP TO 45,000,000 SHARES OF COMMON STOCK UNDERLYING SUCH COMMON WARRANTS*

UP TO 15,000,000 SHARES OF COMMON STOCK UNDERLYING SUCH PRE-FUNDED WARRANTS</div>

We are offering on a reasonable best-efforts basis up to 15,000,000 shares of our common stock, par value $0.01 per share (“ Common Stock”), together with warrants to purchase up to 45,000,000 shares of our Common Stock based on an assumed public offering price of $0.80 per share of Common Stock and accompanying warrant, which was the closing price of our Common Stock on the Nasdaq Stock Market (“ Nasdaq”) on May 9, 2025. Each share of Common Stock, or a pre-funded warrant in lieu thereof, is being sold together with a common warrant to purchase one share of Common Stock. The shares of Common Stock, or pre-funded warrants in lieu thereof, and common warrants are immediately separable and will be issued separately in this offering but must be purchased together in this offering. This prospectus also relates to the shares of Common Stock issuable upon exercise of the pre-funded warrants and the common warrants sold in this offering.

The common warrants will be exercisable upon receipt of stockholder approval, including (i) such approval as may be required by the applicable rules and regulations of Nasdaq from the stockholders of the Company and board of directors of the Company: (a) to consent to any adjustment to the exercise price and/or number of shares of Common Stock underlying the common warrants in the event of an adjustment upon the Adjustment Date (as defined below) pursuant to the terms of the common warrants, (b) to consent to any adjustment to the exercise price of the common warrants in the event of a voluntary adjustment pursuant to the terms of the common warrants, and (c) to consent to the “alternative cashless exercise” provision of the common warrants, in each case without regard to any limitations upon exercise of the common warrants relating to Stockholder Approval (as defined below) and/or the provisions prohibiting adjustments in such common warrants above the price set forth in clause (ii) of the definition of Floor Price (as defined below); and (ii) such approval as may be required from the stockholders of the Company and